Immediate antiretroviral therapy in young HIV-infected children: Benefits and risks

Current Opinion in HIV and AIDS

Volumn 9, Issue 1, 2014, Pages 87-94

  Collins, Intira J ^a   Judd, Ali ^a   Gibb, Diana M ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

antiretroviral therapy; children; immune response; neurodevelopment; survival

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL (TOPIC); DISEASE COURSE; HEALTH HAZARD; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE SYSTEM; INFANT MORTALITY; LONG TERM CARE; NERVE CELL DIFFERENTIATION; PRIORITY JOURNAL; REVIEW; SURVIVAL; TIME TO TREATMENT; TOXICITY; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; CHILD; CHILD DEVELOPMENT; CHILD, PRESCHOOL; COGNITION DISORDERS; DRUG ADMINISTRATION SCHEDULE; HIV INFECTIONS; HUMANS; INFANT; TREATMENT OUTCOME;

EID: 84892373929     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0000000000000027     Document Type: Review

References (57)

1. UNAIDS: A progress report on the Global Plan towards the elimination of new HIV infections among children by 2015 and keeping their mothers alive; 2012. http: //www.unaids.org/en/media/unaids/contentassets/documents/unaids publication/2012/JC2385-ProgressReportGlobalPlan-en.pdf [Accessed 26 February 2013
2. World Health Organization/UNICEF/UNAIDS WH: Global Update on HIV Treatment 2013: Results, Impact and Opportunities. 2013. http: //apps. who.int/iris/bitstream/10665/85326/1/9789241505734-eng.pdf. [Accessed 14 February 2013
3. UNAIDS: 2013 Progress Report on the Global Plan towards the elimination of new HIV infections among children by 2015 and keeping their mothers alive. 2013. http: //www.unaids.org/en/media/unaids/contentassets/documents/ unaidspublication/2013/20130625-progress-global-plan-en.pdf. [Accessed 15 September 2013
4. Newell M-L, Coovadia H, Cortina-Borja M, et al. Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: A pooled analysis. Lancet 2004; 364: 1236-1243
5. Becquet R, Marston M, Dabis F, et al. Children who acquire HIV infection perinatally are at higher risk of early death than those acquiring infection through breastmilk: A meta-Analysis. PLoS One 2012; 7: E28510
6. Joint United Nations Programme on HIV/AIDS (UNAIDS): Global Report: UNAIDS report on the Global AIDS Epidemic.; 2012. http: //www.unaids.org/ en/media/unaids/contentassets/documents/epidemiology/2012/gr2012/ UNAIDS-Global-Report-2012-with-annexes-en.pdf [Accessed 19 August 2013
7. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: Recommendations for a public health approach. 2013; http: //www.who.int/hiv/pub/guidelines/ arv2013/en/index.html. [Accessed 14 August 2013
8. World Health Organization: Scaling up Antiretroviral Therapy in Resource-Limited Settings: Treatment Guidelines for A Public Health Approach; 2003
9. World Health Organization. Antiretroviral therapy of HIV infection in infants and children in resource-limited settings: Towards universal access. Recommendations for a public health approach. 2006; http: //www.who.int/ hiv/pub/guidelines/paediatric020907.pdf [Accessed 30 August 2008
10. World Health Organization: Paediatric HIV Antiretroviral Therapy and Care guideline review: Report of the WHO Technical Reference Group Paediatric HIV/ART Care Guideline Group Meeting. 2008. http: //www.who.int/hiv/ pub/paediatric/WHO-Paediatric-ART-guideline-rev-mreport-2008.pdf [Accessed 30 August 2008
11. World Health Organization: Antiretroviral therapy of HIV infection in infants and children: Towards universal access. Recommendations for a public health approach. 2010. http: //whqlibdoc.who.int/publications/2010/ 9789241599801-eng.pdf [Accessed 19 February 2013
12. Dunn D, Woodburn P, Duong T, et al. Current CD4 cell count and the shortterm risk of AIDS and death before the availability of effective antiretroviral therapy in HIV-infected children and adults. J Infect Dis 2008; 197: 398-404
13. Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children: Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection Edited by; 2012. Centres of Disease Control and Prevention. Developed by the HHS Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children-A Working Group of the Office of AIDS Research Advisory Council (OARAC) http: //aidsinfo.nih.gov/contentfiles/ lvguidelines/ pediatricguidelines.pdf [Accessed 3 March 2013
14. Welch S, Sharland M, Lyall EG, et al. PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV-1 infection. HIV Med 2009; 10: 591-613
15. Okomo U, Togun T, Oko F, et al. Mortality and loss to programme before antiretroviral therapy among HIV-infected children eligible for treatment in The Gambia, West Africa. AIDS Res Ther 2012; 9: 28
16. Sutcliffe C, van Dijk J, Munsanje B, et al. Risk factors for pretreatment mortality among HIV-infected children in rural Zambia: A cohort study. PLoS One 2011; 6: E29294
17. Mugglin C, Wandeler G, Estill J, et al. Retention in care of HIV-infected children from HIV test to start of antiretroviral therapy: Systematic review. PLoS One 2013; 8: E56446
18. Avila D, Patel, K., Chi, B., Wools-Kaloustian, K., Leroy, V., Sohn, A., Chimbetete, C., Hazra, R., Egger, M., Davies, M.A., Severe Immunodeficiency in Children Starting ART in Low-, Middle-And High-income Countries (Poster #940). In 20th Conference on Retroviruses and Opportunistic Infections. Edited by. Georgia, USA; 2013
19. Leroy V, Malateste K, Rabie H, et al. Outcomes of antiretroviral therapy in children in Asia and Africa: A comparative analysis of the IeDEA pediatric multiregional collaboration. J Acquir Immune Defic Syndr 2013; 62: 208-219; 210.1097/QAI.1090b1013e31827b31870bf
20. Kabue MM, Buck WC, Wanless SR, et al. Mortality and clinical outcomes in HIV-infected children on antiretroviral therapy in Malawi, Lesotho, and Swaziland. Pediatrics 2012; 130: E591-e599
21. TREAT Asia Pediatric Observational Cohort (TApHOD) International Epidemiologic Databases to Evaluate AIDS (IeDEA) Southern Africa Paediatric Group. A biregional survey and review of first-line treatment failure and second-line paediatric antiretroviral access and use in Asia and southern Africa. J Int AIDS Soc 2011; 14: 7
22. HIV Paediatric Prognostic Markers Collaborative Study Group (HPPMCS). Sort-Term risk of disease progression in HIV-1-infected children receiving no antiretroviral therapy or zidovudine monotherapy: A meta-Analysis. Lancet 2003; 362: 1605-1611
23. Cross Continents Collaboration for Kids (3Cs4kids) Analysis and Writing Committee. Markers for predicting mortality in untreated HIV-infected children in resource-limited settings: A meta-Analysis. AIDS 2008; 22: 97-105
24. Violari A, Cotton MF, Gibb DM, et al. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med 2008; 359: 2233-2244
25. Cotton MF, Violari A, Otwombe K, et al. Early time-limited antiretroviral therapy versus deferred therapy in South African infants infected with HIV: Results from the children with HIV early antiretroviral (CHER) randomised trial. Lancet 2013; http: //www.thelancet.com/journals/lancet/article/PIIS0140- 6736(13) 61409-9/abstract. [Epub ahead of print
26. Violari A, Cotton MF, Gibb DM, et al. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med 2008; 359: 2233-2244
27. Laughton B, Cornell M, Grove D, et al. Early antiretroviral therapy improves neurodevelopmental outcomes in infants. AIDS 2012; 26: 1685-1690
28. Puthanakit T, Saphonn V, Ananworanich J, et al. Early versus deferred antiretroviral therapy for children older than 1 year infected with HIV (PREDICT): A multicentre, randomised, open-label trial. Lancet Infect Dis 2012; 12: 933-941
29. Puthanakit T, Ananworanich J, Vonthanak S, et al. Cognitive function and neurodevelopmental outcomes in HIV-infected children older than 1 year of age randomized to early versus deferred antiretroviral therapy: The PREDICT neurodevelopmental study. Pediatr Infect Dis J 2013; 32: 501-508
30. McConnell MS, Chasombat S, Siangphoe U, et al. National program scale-up and patient outcomes in a pediatric antiretroviral treatment program, Thailand 2000-2007. J Acquir Immune Defic Syndr 2010; 54: 423-429
31. Collins IJ, Jourdain G, Hansudewechakul R, et al. Long-Term survival of HIVinfected children receiving antiretroviral therapy in Thailand: A 5-year observational cohort study. Clin Infect Dis 2010; 51: 1449-1457
32. M-A. Davies, M. Schomaker, T. Gsponer, J. Ndirangu, S. Phiri, H. Moultrie, K. Technau, V. Cox, J. Giddy, C. Chimbetete, et al. When to start ART in children aged 2-5 years? Causal modeling analysis of IeDEA southern Africa (TUPE313). In 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Edited by Kuala Lumpur, Malaysia; 2013
33. Patel K, Hernan MA, Williams PL, et al. Long-Term effects of highly active antiretroviral therapy on CD4 cell evolution among children and adolescents infected with HIV: 5 years and counting. Clin Infect Dis 2008; 46: 1751-1760
34. Puthanakit T, Kerr SJ, Ananworanich J, et al. Pattern and predictors of immunologic recovery in human immunodeficiency virus-infected children receiving non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy. Pediatr Infect Dis J 2009; 28: 488-492
35. Soh CH, Oleske JM, Brady MT, et al. Long-Term effects of protease-inhibitorbased combination therapy on CD4 T-cell recovery in HIV-1-infected children and adolescents. Lancet 2003; 362: 2045-2051
36. Walker AS, Doerholt K, Sharland M, Gibb DM, Collaborative HIV Paediatric Study CHIPS Steering Committee. Response to highly active antiretroviral therapy varies with age: The UK and Ireland Collaborative HIV Paediatric Study. AIDS 2004; 18: 1915-1924
37. Lewis J, Walker AS, Castro H, et al. Age and CD4 count at initiation of antiretroviral therapy in HIV-infected children: Effects on long-Term T-cell reconstitution. J Infect Dis 2012; 205: 548-556
38. ARROW Trial team. Routine versus clinically driven laboratory monitoring and first-line antiretroviral therapy strategies in African children with HIV (ARROW): A 5-year open-label randomised factorial trial. Lancet 2013; 381: 1391-1403
39. Collins I, Ngo-Giang-Huong N, Jourdain G, Chanta C, Puangsombat A, Kwanchaipanich R, Bunjongpak S, Cressey T, Le Coeur S, Jaffar S, et al. Long-Term immune response in HIV-infected children receiving highly active antiretroviral therapy in Thailand: Outcomes at 7-years. In 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Edited by Kuala Lumpur, Malaysia (#TUPE314).; 2013
40. Lapadula G, Cozzi-Lepri A, Marchetti G, et al. Risk of clinical progression among patients with immunological nonresponse despite virological suppression after combination antiretroviral treatment. AIDS 2013; 27: 769-779; 710.1097/QAD.1090b1013e32835cb32747
41. Gilson R, Man SL, Copas A, et al. Discordant responses on starting highly active antiretroviral therapy: Suboptimal CD4 increases despite early viral suppression in the UK Collaborative HIV Cohort (UK CHIC) Study-. HIV Med 2010; 11: 152-160
42. The Collaboration of Observational HIV Epidemiological Research Europe in EuroCoord. All-cause mortality in treated HIV-infected adults with CD4-500/ mm3 compared with the general population: Evidence from a large European observational cohort collaboration. Int J Epidemiol 2012; 41: 433-445
43. Lewden C, Chêne G, Morlat P, et al. HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-Term combination antiretroviral therapy reach same mortality rates as the general population. J Acquir Immune Defic Syndr 2007; 46: 72-77; 10.1097/QAI.1090b1013e318134257a
44. Laughton B, Cornell M, Boivin M, Van Rie A. Neurodevelopment in perinatally HIV-infected children: A concern for adolescence. J Int AIDS Soc 2013; 16: 18603
45. Le Doaré K, Bland R, Newell M-L. Neurodevelopment in children born to HIV-infected mothers by infection and treatment status. Pediatrics 2012; 130: E1326-e1344
46. Ruel TD, Boivin MJ, Boal HE, et al. Neurocognitive and motor deficits in HIVinfected Ugandan children with high CD4 cell counts. Clin Infect Dis 2012; 54: 1001-1009
47. Smith R, Chernoff M, Williams PL, et al. Impact of HIV severity on cognitive and adaptive functioning during childhood and adolescence. Pediatr Infect Dis J 2012; 31: 592-598; 10.1097/INF.1090b1013e318253844b
48. Barlow-Mosha L, Eckard AR, McComsey GA, Musoke PM. Metabolic complications and treatment of perinatally HIV-infected children and adolescents. J Int AIDS Soc 2013; 16: 18600
49. Bhimma R, Purswani MU, Kala U. Kidney disease in children and adolescents with perinatal HIV-1 infection. J Int AIDS Soc 2013; 16: 18596
50. Puthanakit T, Siberry GK. Bone health in children and adolescents with perinatal HIV infection. J Int AIDS Soc 2013; 16: 18575
51. Davies MA, Moultrie H, Eley B, et al. Virologic failure and second-line antiretroviral therapy in children in South Africa: The IeDEA Southern Africa collaboration. J Acquir Immune Defic Syndr 2011; 56: 270-278
52. Lowenthal ED, Ellenberg JH, Machine E, et al. Association between efavirenzbased compared with nevirapine-based antiretroviral regimens and virological failure in HIV-infected children. JAMA 2013; 309: 1803-1809
53. Collins I, Cairns J, Le Coeur S, et al. Five-year trends in antiretroviral usage and drug costs in HIV-infected children in Thailand. J Acquir Immune Defic Syndr 2013; 64: 95-102; 110.1097/QAI.1090b1013e318298a318309
54. Castro H, Judd A, Gibb DM, et al. Risk of triple-class virological failure in children with HIV: A retrospective cohort study. Lancet 2011; 377: 1580-1587
55. Kuhn L, Coovadia A, Strehlau R, et al. Switching children previously exposed to nevirapine to nevirapine-based treatment after initial suppression with a protease-inhibitor-based regimen: Long-Term follow-up of a randomised, openlabel trial. Lancet Infect Dis 2012; 12: 521-530
56. Paediatric European Network for Treatment of AIDS. Response to planned treatment interruptions in HIV infection varies across childhood. AIDS 2010; 24: 231-241; 210.1097/QAD.1090b1013e328333d328343
57. Bunupuradah T, Duong T, Compagnucci A, et al. Outcomes after reinitiating antiretroviral therapy in children randomized to planned treatment interruptions. AIDS 2013; 27: 579-589; 510.1097/QAD.1090b1013e32835c31181